Autologous transplantation in follicular lymphoma with early therapy failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research analysis Journal Article
| Authors: | Casulo, C.; Friedberg, J. W.; Ahn, K. W.; Flowers, C.; DiGilio, A.; Smith, S. M.; Ahmed, S.; Inwards, D.; Aljurf, M.; Chen, A. I.; Choe, H.; Cohen, J.; Copelan, E.; Farooq, U.; Fenske, T. S.; Freytes, C.; Gaballa, S.; Ganguly, S.; Jethava, Y.; Kamble, R. T.; Kenkre, V. P.; Lazarus, H.; Lazaryan, A.; Olsson, R. F.; Rezvani, A. R.; Rizzieri, D.; Seo, S.; Shah, G. L.; Shah, N.; Solh, M.; Sureda, A.; William, B.; Cumpston, A.; Zelenetz, A. D.; Link, B. K.; Hamadani, M. |
| Article Title: | Autologous transplantation in follicular lymphoma with early therapy failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research analysis |
| Abstract: | Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. We identified 2 groups: the non-autoHCT cohort (patients from the NLCS with ETF not undergoing autoHCT) and the autoHCT cohort (CIBMTR patients with ETF undergoing autoHCT). All patients received rituximab-based chemotherapy as frontline treatment; 174 non-autoHCT patients and 175 autoHCT patients were identified and analyzed. There was no difference in 5-year OS between the 2 groups (60% versus 67%, respectively; P =.16). A planned subgroup analysis showed that patients with ETF receiving autoHCT soon after treatment failure (≤1 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73% versus 60%, P =.05). On multivariate analysis, early use of autoHCT was associated with significantly reduced mortality (hazard ratio,.63; 95% confidence interval,.42 to.94; P =.02). Patients with FL experiencing ETF after frontline chemoimmunotherapy lack optimal therapy. We demonstrate improved OS when receiving autoHCT within 1 year of treatment failure. Results from this unique collaboration between the NLCS and CIBMTR support consideration of early consolidation with autoHCT in select FL patients experiencing ETF. © 2017 The American Society for Blood and Marrow Transplantation |
| Keywords: | rituximab; follicular lymphoma; autologous transplantation; chemoimmunotherapy; early therapy failure; early transplant |
| Journal Title: | Biology of Blood and Marrow Transplantation |
| Volume: | 24 |
| Issue: | 6 |
| ISSN: | 1083-8791 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-06-01 |
| Start Page: | 1163 |
| End Page: | 1171 |
| Language: | English |
| DOI: | 10.1016/j.bbmt.2017.12.771 |
| PROVIDER: | scopus |
| PMCID: | PMC5993598 |
| PUBMED: | 29242111 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 July 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work